<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041543</url>
  </required_header>
  <id_info>
    <org_study_id>NTX-101-P1</org_study_id>
    <nct_id>NCT05041543</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of NTX-101 in Korean Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of NTX-101 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pinotbio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pinotbio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blinded, placebo controlled, multiple dose, randomized, single site, phase 1&#xD;
      clinical trial to evaluate safety, tolerability, and pharmacokinetics of NTX-101 topical eye&#xD;
      drop in Korean healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluation: Incidence, type, and severity of Adverse Events (AE)</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose, 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours after first and last administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area under the curve (AUC)</measure>
    <time_frame>Pre-dose, 15, 30, 45 minutes, 1, 2, 3, 4, 6, 8, 12, 24 hours after first and last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>NTX-101 Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: One time administration, single drop. 4 subjects randomized 3:1 to NTX-101 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTX-101 Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTX-101 Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: One time administration, single drop. Day 3-7: Two time administration, one drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTX-101 Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: One time administration, two drops. Day 3-7: Two time administration, two drops each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NTX-101 Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: One time administration, four drops. Day 3-7: Two time administration, four drop each time (12 hours apart). Total 9 times administration. 8 subjects randomized 6:2 to NTX-101 or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTX-101</intervention_name>
    <description>Eye drops, topical administration</description>
    <arm_group_label>NTX-101 Group A</arm_group_label>
    <arm_group_label>NTX-101 Group B</arm_group_label>
    <arm_group_label>NTX-101 Group C</arm_group_label>
    <arm_group_label>NTX-101 Group D</arm_group_label>
    <arm_group_label>NTX-101 Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo as eye drops</description>
    <arm_group_label>NTX-101 Group A</arm_group_label>
    <arm_group_label>NTX-101 Group B</arm_group_label>
    <arm_group_label>NTX-101 Group C</arm_group_label>
    <arm_group_label>NTX-101 Group D</arm_group_label>
    <arm_group_label>NTX-101 Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult subjects who have voluntarily agreed to the participation of this study&#xD;
             upon sufficient explanation of the purpose, procedure, and the characteristics of the&#xD;
             experimental drug of the trial prior to participation&#xD;
&#xD;
          2. Subjects of ages between 19 and 45 years inclusive and with Body Mass Index (BMI)&#xD;
             between 18.0 and 27.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical History&#xD;
&#xD;
               -  Subjects with a clinically significant history of the gastrointestinal, hepatic,&#xD;
                  cardiovascular, pulmonary, endocrine, renal, urological, immunologic,&#xD;
                  musculoskeletal, neurological, psychiatric, hematological, ocular,&#xD;
                  otolaryngologic disorder not deemed acceptable by the PI&#xD;
&#xD;
               -  Subjects with a clinically significant history of disorder that can affect the&#xD;
                  experimental drug's absorption, distribution, metabolism, and excretion (e.g.&#xD;
                  Crohn's disease, peptic ulcer, surgery to stomach and intestine (excluding&#xD;
                  appendectomy and herniorrhaphy)) not deemed acceptable by the PI&#xD;
&#xD;
          2. Ocular History&#xD;
&#xD;
               -  Subjects with a suspected history or symptoms of visual organ disorder, including&#xD;
                  keratitis, uveitis, retinitis, dry eye syndrome, and strabismus.&#xD;
&#xD;
               -  Subjects with corrected visual acuity of below 20/40 (0.5 in Han Chun Suk chart)&#xD;
&#xD;
               -  Subjects with history of ocular surgery, excluding those who received laser eye&#xD;
                  surgery 6 months prior to screening&#xD;
&#xD;
               -  Subjects who have experienced complications from wearing contact lens, used&#xD;
                  contact lens in the past month, or cannot adhere to the prohibition of using&#xD;
                  contact lens during the study&#xD;
&#xD;
               -  Subjects with other anomalies discovered at the ocular examination upon screening&#xD;
&#xD;
          3. Clinical Examination&#xD;
&#xD;
               -  Subjects with a resting blood pressure of &gt;140 mmHg or &lt;90 mmHg diastolic, &gt;90&#xD;
                  mmHg or &lt;60 mmHg systolic, or heartrate exceeding 100 per minute&#xD;
&#xD;
               -  Subjects with inadequate levels of the following criteria upon repeated&#xD;
                  examination&#xD;
&#xD;
                    1. AST or ALT &gt;1.25 x upper limit of normal level&#xD;
&#xD;
                    2. Total bilirubin &gt;1.5 x upper limit of normal&#xD;
&#xD;
                    3. eGFR level from CKD-EPI equation &lt; 90 mL/min/1.73m²&#xD;
&#xD;
                    4. Positive blood serum result (HBsAg, HCV Ab, HIV Ab, Syphilis reagin test)&#xD;
&#xD;
               -  Subjects who show anomalies or have the following results repeatedly in the&#xD;
                  electrocardiogram (including, but not limited to, major arrhythmia, multifocal&#xD;
                  PVC, 2° A-V block anomaly, etc.)&#xD;
&#xD;
                    1. PR interval ≥ 210msec&#xD;
&#xD;
                    2. QRS complex ≥ 120msec&#xD;
&#xD;
                    3. QTcF interval ≥ 450msec&#xD;
&#xD;
          4. Allergy, Hypersensitivity, or Substance Abuse&#xD;
&#xD;
               -  Subjects with hypersensitivity to the components or additives of the experimental&#xD;
                  drug&#xD;
&#xD;
               -  Subjects with clinically significant allergy (excluding mild allergic rhinitis&#xD;
                  that does not require medication) or prior history of hypersensitivity to other&#xD;
                  drugs (aspirin, antibiotics, etc.)&#xD;
&#xD;
               -  Subject with history of substance abuse (especially drugs that act on Central&#xD;
                  Nervous System, such as sedatives, Central Nervous System depressants, opioids,&#xD;
                  or psychotropic drugs, etc.) or positive result from screening test&#xD;
                  (methamphetamine, marijuana, opium, cocaine, amphetamine, ecstasy)&#xD;
&#xD;
          5. Prohibited drug/food&#xD;
&#xD;
               -  Subjects who have taken drug metabolism stimulator or suppressor within 1 month&#xD;
                  of the first experimental drug administration&#xD;
&#xD;
               -  Subjects who have received vaccination within 8 weeks prior to the first&#xD;
                  experimental drug administration or is expecting to receive before the end of&#xD;
                  study&#xD;
&#xD;
               -  Subjects who have taken prescribed medicine (including prescribed herbal&#xD;
                  medicine) 14 days prior or over-the-counter drugs (including vitamin supplements)&#xD;
                  10 days prior to the administration of the experimental drugs that may affect the&#xD;
                  study determined by the PI&#xD;
&#xD;
               -  Subjects who have taken within 7 days prior to the first administration of the&#xD;
                  experimental drug or cannot stop taking food that may affect the drug's&#xD;
                  absorption, distribution, metabolism, and excretion (e.g. grapefruit juice,&#xD;
                  garlic extract, broccoli, kale, etc.)&#xD;
&#xD;
               -  Subjects who have participated in other pharmacokinetic or other clinical studies&#xD;
                  and have taken experimental drugs 6 months prior to this study&#xD;
&#xD;
          6. Blood Donation and Transfusion&#xD;
&#xD;
               -  Subjects who have donated whole blood within 2 months prior to the first&#xD;
                  administration of the experimental drug or have donated blood components within 1&#xD;
                  month prior to the administration of the experimental drug&#xD;
&#xD;
               -  Subjects who have received blood transfusion within 1 month prior to the&#xD;
                  administration of the experimental drug&#xD;
&#xD;
          7. Contraceptives&#xD;
&#xD;
               -  Subjects who use inadequate contraceptives during the study that have not been&#xD;
                  clinically accepted&#xD;
&#xD;
                    1. Use of intrauterine device that have been proved to prevent pregnancy&#xD;
&#xD;
                    2. Use of condoms (male or female) with spermicide&#xD;
&#xD;
                    3. Vasectomy&#xD;
&#xD;
                    4. Tubal ligation or hysterectomy&#xD;
&#xD;
                    5. Sperm donation during the study period&#xD;
&#xD;
          8. Others&#xD;
&#xD;
               -  Subjects who refuses to stop taking xanthine-containing food from 3 days prior to&#xD;
                  the first administration of the experimental drug until the end of study (e.g.&#xD;
                  coffee, green tea, black tea, cola, cocoa, chocolate, energy drinks, etc.)&#xD;
&#xD;
               -  Subjects who refuses to stop drinking excessive alcohol (&gt;30 g/day) from 3 days&#xD;
                  prior to the first administration of the experimental drug until the end of study&#xD;
&#xD;
               -  Subjects who refuses to stop smoking during the hospitalization period&#xD;
&#xD;
               -  Subjects deemed unfit for this study by the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47323</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ophthalmic Solutions</keyword>
  <keyword>Eye Drops</keyword>
  <keyword>Eye Diseases</keyword>
  <keyword>Ischemic Optic Neuropathy</keyword>
  <keyword>Glaucoma</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

